tiprankstipranks
Axsome Therapeutics expects cash to fund operations into cash flow positivity
PremiumThe FlyAxsome Therapeutics expects cash to fund operations into cash flow positivity
2d ago
Axsome Therapeutics reports Q1 EPS ($1.44), consensus ($1.20)
PremiumThe Fly
Axsome Therapeutics reports Q1 EPS ($1.44), consensus ($1.20)
2d ago
AXSM Earnings this Week: How Will it Perform?
PremiumPre-Earnings
AXSM Earnings this Week: How Will it Perform?
4d ago
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
PremiumPress ReleasesAxsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
28d ago
Axsome Therapeutics initiates ENGAGE Phase 3 trial of solriamfetol
PremiumThe Fly
Axsome Therapeutics initiates ENGAGE Phase 3 trial of solriamfetol
1M ago
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
PremiumPress Releases
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
1M ago
Citi ups Axsome Therapeutics target, says selloff unwarranted
PremiumThe FlyCiti ups Axsome Therapeutics target, says selloff unwarranted
1M ago
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
PremiumPress Releases
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
1M ago
Axsome Therapeutics announces results of CRESCENDO narcolepsy survy
PremiumThe Fly
Axsome Therapeutics announces results of CRESCENDO narcolepsy survy
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100